Related Experiment Video
Updated: Nov 9, 2025

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
Doxorubicin cardiomyopathy is associated with a decrease in calcium release channel of the sarcoplasmic reticulum in
D A Dodd1, J B Atkinson, R D Olson
1Division of Pediatric Cardiology, Vanderbilt University Medical Center, Nashville, Tennessee 37232.
Abstract:
Doxorubicin is a highly effective cancer chemotherapeutic agent that produces a dose-dependent cardiomyopathy that limits its clinical usefulness. Clinical and animal studies of morphological changes during the early stages of doxorubicin-induced cardiomyopathy have suggested that the sarcoplasmic reticulum, the intracellular membrane system responsible for myoplasmic calcium regulation in adult mammalian heart, may be the early target of doxorubicin. To detect changes in the calcium pump protein or the calcium release channel (ryanodine receptor) of the sarcoplasmic reticulum during chronic doxorubicin treatment, rabbits were treated with intravenous doxorubicin (1 mg/kg) twice weekly for 12 to 18 doses. Pair-fed controls received intravenous normal saline. The severity of cardiomyopathy was scored by light and electron microscopy of left ventricular papillary muscles. Developed tension was measured in isolated atrial strips. In subcellular fractions from heart, [3H]ryanodine binding was decreased in doxorubicin-treated rabbits (0.33 +/- 0.03 pmol/mg) compared with control rabbits (0.66 +/- 0.02 pmol/mg; P < 0.0001). The magnitude of the decrease in [3H]ryanodine binding correlated with both the severity of the cardiomyopathy graded by pathology score (light and electron microscopy) and the decrease in developed tension in isolated atrial strips. Bmax for [3H]ryanodine binding and the amount of immunoreactive ryanodine receptor by Western blot analysis using sequence-specific antibody were both decreased, consistent with a decrease in the amount of calcium release channel of sarcoplasmic reticulum in doxorubicin-treated rabbits. In contrast, there was no decrease in the amount or the activity of the calcium pump protein of the sarcoplasmic reticulum in doxorubicin-treated rabbits. Doxorubicin treatment did not decrease [3H]ryanodine binding or the amount of immunoreactive calcium release channel of sarcoplasmic reticulum in skeletal muscle. Since the sarcoplasmic reticulum regulates muscle contraction by the cyclic uptake and release of a large internal calcium pool, altered function of the calcium release channel could lead to the abnormalities of contraction and relaxation observed in the doxorubicin cardiomyopathy.
Insights
Doxorubicin chemotherapy damages heart muscle by reducing the sarcoplasmic reticulum
Area of Science:
- Cardiology
- Oncology
- Biochemistry
Background:
- Doxorubicin is a vital chemotherapy drug.
- It can cause dose-dependent cardiomyopathy, limiting its use.
- The sarcoplasmic reticulum (SR) may be an early target in this damage.
Purpose of the Study:
- To investigate changes in SR calcium pump and release channel proteins during doxorubicin treatment.
- To correlate these changes with cardiomyopathy severity and functional deficits.
Main Methods:
- Rabbits received chronic doxorubicin treatment.
- Cardiomyopathy was assessed via microscopy.
- SR protein levels and function ([3H]ryanodine binding, Western blot) were measured in heart and skeletal muscle.
Main Results:
- Doxorubicin significantly decreased [3H]ryanodine binding and ryanodine receptor levels in heart SR.
- These decreases correlated with cardiomyopathy severity and reduced atrial contractility.
- No changes were observed in the SR calcium pump protein or in skeletal muscle SR.
Conclusions:
- Doxorubicin-induced cardiomyopathy involves a reduction in cardiac sarcoplasmic reticulum calcium release channels (ryanodine receptors).
- This dysfunction likely contributes to the observed contraction and relaxation abnormalities.
- The calcium pump protein remains unaffected, suggesting a specific impact on the release channel.
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy II: Dilated Cardiomyopathy

